Micrognathia, Schizophrenia
Conditions
Brief summary
This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.
Detailed description
The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR). The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least. This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.
Interventions
Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
OTHERatypical antipsychotic combined with MECT
The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
Sponsors
TAKARA BIOTECHNOLOGY(DALIAN)CO.,LTD.
Dalian Seventh People's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
17 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Persons should be diagnosed with schizophrenia according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) * The first-onset or drug-free in the latest 3 months * Between the ages of 17-40
Exclusion criteria
* Comorbid with other psychosis * Have physical or neurological diseases such as traumatic brain injuries * History of drug-abused or alcoholic * Blood transfusion history in a month * Been treated with Modified Electric Convulsive Therapy(MECT) in late 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) | before the treatment | the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection |
| the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) | Change from Baseline expression level at 4-week treatment | the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia | before, after 4 weeks and 8 weeks treatment | The PANSS for estimating the severity of positive and negative symptoms in schizophrenia |
| The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia | before, after 4 weeks and 8 weeks treatment | The degree of Personal and Social Performance scale(PSP) used to evaluate the disable levels in Multiple dimensions ,especially in social and self-care performance |
| The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment | 4 weeks and 8 weeks treatment | Main purpose to provide a global rating of illness severity ,improvement and response to treatment for the patients with schizophrenia |
Countries
China
Contacts
Primary ContactGuanghui Fu, postgraduate
Backup ContactShoufu Xie, postgraduate
Outcome results
None listed